• Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Most-Read Conference Coverage of 2022

Article

Conference season was a busy one this year with many stories to come out each one MHE covered. The most-read conference stories from our audience began with Atopic Dermatitis treatment at AMCP to discussion series with PBM leader Alan Lotvin of CVS Caremark.

  1. AMCP 2022: Atopic Dermatitis Treatment is a Good News Story, Say Symposium Panelists
    Dupixent (dupilumab) ushered in a new era and a growing number of treatment options has brought awareness to the condition. But the panelists also discussed problems with step therapy, delays and denials of treatment and the lack of a “gold standard” test for diagnosis.
    Read more
  2. Weight-Loss Drugs: Why This Time It May Be a Different Story | 2022 PBMI Annual National Conference
    The harm caused by weight-loss drugs have overwhelmed any benefit they may have. The repurposed diabetes drugs like Wegovy (semaglutide) have a strong safety profile, said presented at the annual Pharmacy Benefit Management Institute meeting.
    Read more
  3. Specialty Pharmacy Controls Limit Patient Access, Fein and Long Explain: 2022 Asembia Specialty Pharmacy Summit
    In their general session, Adam J. Fein, PhD of Drug Channels Institute, and Doug Long of IQVIA reviewed the current specialty pharmacy space, ongoing trends and future expectations.
    Read more
  4. 2022 PBMI National Meeting Kicks Off Monday
    Agenda includes sessions on overall trends in the pharmacy benefit management industry, digital therapeutics and biosimilars.
    Read more
  5. A Conversation with Alan Lotvin, M.D. on the PBM Industry’s Reputation | Part 1
    The president of CVS Caremark discusses the PBM industry’s reputation, list prices and rebates.
    Read more










Related Videos
Video 6 - "Navigating Insurance Coverage for Prescription Digital Therapeutics"
Video 5 - "FDA Approval Pathway for Prescription Digital Therapeutics"
Video 8 - "Gaps in Evidence Generation for Digital Therapeutics"
Video 7 - "Adoption Lessons For Payers"
Video 10 - "Managing Self Care"
Video 3 - "Embracing and Improving Access to Technology Tools"
Video 4 - "Assessing the Cost-Effectiveness of Prescription Digital Therapeutics "
Related Content
© 2024 MJH Life Sciences

All rights reserved.